[Therapy-related AML(M2) with t(8;21) that developed three years after chemotherapy for hepatocellular carcinoma].
A 60-year-old male with hepatocellular carcinoma was treated by repeated intra-arterial injection of epirubicin, carboplatin and doxorubicin. Subsequently, radiotherapy and intravenous administration of etoposide were also carried out. Thirty-three months later he developed AML (M2). The chromosome analysis revealed 45, X, -Y, t (8;21) (q22;q22), which suggested that this leukemia was induced by topoisomerase II targeting agents. He was treated with low dose BHAC and G-CSF and achieved complete remission. This leukemia may be caused by synergic effect of topoisomerase II inhibitors and carboplatin together with radiotherapy. This may be the first report of therapy-related leukemia following chemotherapy for hepatocellular carcinoma.
Miyata
A
A
Department of Internal Medicine, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama City, Japan.
Deguchi
S
S
Fujita
M
M
Kikuchi
T
T
Honda
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D004317:Doxorubicin / Q000009:adverse effects; D015251:Epirubicin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics; D014178:Translocation, Genetic
D015251:Epirubicin; D005047:Etoposide; D004317:Doxorubicin; D016190:Carboplatin